Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction.

Abstract: A bioabsorbable brachytherapy device includes a tubular housing with sealed ends and an enclosed radioactive material. The radioactive material includes a radioisotope, such as palladium-103 or iodine-125. The tubular housing is made from a biocompatible and bioabsorbable polymeric material, and is sealed by means such as heat welding or solvent fixing. The device may further include a radiopaque medium and one or more therapeutic drugs.

Abstract: A method for making a hydrophilic and lubricious coating, the coating so made and a medical device including such coating, wherein the coating includes a hydrophilic polymeric unit layer cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C═C, C═N or C═O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol. The invention also provides products containing such coatings and their uses in medical, pharmaceutical and cosmetic applications.

Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.

Abstract: A nucleic acid coating composition including a polyanion bound, directly or through one or more intermediates, to a medical device surface, with a condensate comprising a polycation and nucleic acid bound to the polyanion, devices incorporating such coating compositions, and methods for making. In one embodiment, a silyl-heparin complex is provided, bound to a medical device surface by hydrophobic interaction with the silyl moiety, with a polycation and nucleic acid condensate bound to the heparin by electrostatic interaction.

Abstract: The present invention provides an anti-thrombogenic and cellular-adhesion coating composition for blood-contacting surfaces. The coating comprises a covalent complex of from 1 to 30 hydrophobic silyl moieties of Formula I: wherein R1 is an C1-18 alkyl or C6-32 aryl group, each R2 is independently selected from the group consisting of C1-18 alkyl and C6-32 aryl, R3 is N or O, n is a number from 1 to 10, directly bound to a heparin molecule via covalent bonding, with an adhesive molecule directly bound to the heparin molecule. In one embodiment, the coating comprises benzyl-(1,2 dimethyl)disilyl heparin, wherein an adhesive molecule, such as fibronectin, is bound to the heparin.

Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue is modified by plasma treatment in a plasma comprising nitrogen-containing molecules and oxygen-containing molecules. The nitrogen-containing molecules include NH3, (NH4)+, N2O, NO, NO2 and N2O4, and the oxygen-containing molecules include O2 and O3. The plasma-modified contacting surface exhibits decreased adhesion of at least some mammalian cells, such as platelets and leukocytes, decreased restenosis when used with stents, and increased apoptosis. Additional layers may be applied, including plasma polymerized hydrocyclosiloxane monomers, amine-providing groups such as N-trimethylsilyl-allylamine, polyoxyalkylene tethers, and bioactive compounds.

Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.

Abstract: A bioabsorbable brachytherapy device includes a tubular housing with sealed ends and an enclosed radioactive material. The radioactive material includes a radioisotope, such as palladium-103 or iodine-125. The tubular housing is made from a biocompatible and bioabsorbable polymeric material, and is sealed by means such as heat welding or solvent fixing. The device may further include a radiopaque medium and one or more therapeutic drugs.

Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.

Abstract: Combination radiation delivery and chemotherapy devices comprise bioabsorbable structures with radionuclides and chemotherapeutic agents immobilized on said structures. The bioabsorbable structures have a predefined persistence period which is usually substantially greater than the half-life of the radionuclides, thus assuring that the radionuclides remain localized and sequestered at a desired target site while significant radioactivity remains. The radiation delivery and chemotherapy devices are suitable for a wide variety of medical purposes, being particularly suitable for the treatment of solid tumors by injection or open surgical introduction of the devices at a target site. Kits comprising the devices together with instructions for use are also provided.

Abstract: The subject invention relates to the use of ascorbic acid and derivatives thereof in stabilizing radiolabeled proteins and peptides against oxidation loss of radiolabel and autoradiolysis. Ascorbic acid is added after radiolabeling, including any required incubation period, but prior to patient administration.

Abstract: The invention relates to radiotherapy with somatostatin-derived peptides labeled with medically useful metal ions. The invention in particular provides for methods and reagents for labeling somatostatin-derived peptides with perrhenate, in which a solution including somatostatin-derived peptide analogue containing at least one disulfide bond is provided, the solution is reacted with stannous ions and with a radioisotope, wherein the stannous ions are sufficient to substantially reduce the disulfide bonds of the peptide and the radioisotope, and the radiolabeled somatostatin-derived peptide analogue recovered. Also provided are methods for regional administration of radiolabeled somatostatin-derived peptides, methods for enhanced regional retention of radiolabeled somatostatin-derived peptides, methods for treatment of arthritis using radiolabeled somatostatin derived peptides, and methods for stabilizing radiolabeled somatostatin derived peptides.

Abstract: Proteins containing one or more disulfide bonds or monosulfides are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. Labeling is accomplished with a variety of metals, including radiometals, by using a reducing agent to reduce the disulfide bonds to thiolate groups; excess reducing agent, reaction by-products and any impurities are removed; and, a source of Sn (II) agent is added to the thiolate-containing protein. The resulting product may be stored frozen or lyophilized, with labeling accomplished by the addition of the medically useful metal ions.

Abstract: High affinity linked, branched or linear repeat peptides containing two or more biological-function domains and at least one medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, including diagnosis and treatment of diseases. Such peptides include high affinity chemotactic peptides containing a biological-function domain which includes at least two linked N-formyl-MLF (SEQ. ID NO. 2) sequences and high affinity repeat and branched peptides containing two or more YIGSR (SEQ. ID NO. 1) sequences.

Abstract: Peptides containing a biological-function domain and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. The peptides have the amino acid sequence(R.sub.1)--?Y.sub.1 !.sub.n --(R.sub.2),(R.sub.1)--?Y.sub.1 --(R.sub.2)--Y.sub.1 !.sub.n --(R.sub.3)and(R.sub.1)--?Y.sub.1 --(R.sub.2)--Y.sub.2 !.sub.n --(R.sub.3)wherein the medically useful metal ion-binding domain is ?Y.sub.1 !.sub.n, ?Y.sub.1 --(R.sub.2)--Y.sub.1 !.sub.n or ?Y.sub.1 --(R.sub.2)--Y.sub.2 !.sub.n, in which n is a number between 1 and about 6 and Y.sub.1 and Y.sub.2 are amino acids with a sulfur, nitrogen or oxygen which is available for binding to metal ions, or can be made available for binding to metal ions; the biological-function domain is an amino acid sequence containing from 1 to about 20 amino acids located in any one or more of R.sub.1, R.sub.2 or R.sub.3 ; and those portions of R.sub.1, R.sub.2 and R.sub.

Abstract: Peptides useful for lung imaging, and preferably containing a biological-function domain which includes the sequence Ile-Lys-Val-Ala-Val (IKVAV) (SEQ. ID NO. 1) and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, and particularly diagnostic imaging of diseases and pathologic conditions of the lung.

Abstract: Peptides useful for lung imaging, and preferably containing a biological-function domain which includes the sequence Ile-Lys-Val-Ala-Val (IKVAV) (SEQ. ID NO.: 1) and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, and particularly diagnostic imaging of diseases and pathologic conditions of the lung.

Abstract: High affinity chemotactic peptides containing a biological-function domain which includes at least two linked N-formyl-Met-Leu-Phe sequences and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in a variety of diseases and pathologic conditions, and particularly for diagnosis and treatment of infections, inflammations and other diseases and conditions.

Abstract: Peptides containing a biological-function domain and a medically useful metal ion-binding domain are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. The peptides have the amino acid sequence(R.sub.1)--?Y.sub.1 !.sub.n --(R.sub.2),(R.sub.1)--?Y.sub.1 --(R.sub.2)--Y.sub.1 !.sub.n --(R.sub.3) and(R.sub.1)--?Y.sub.1 --(R.sub.2)--Y.sub.2 !.sub.n --(R.sub.3)wherein the medically useful metal ion-binding domain is ?Y.sub.1 !.sub.n, ?Y.sub.1 --(R.sub.2)--Y.sub.1 !.sub.n or ?Y.sub.1 --(R.sub.2)--Y.sub.2 !.sub.n, in which n is a number between 1 and about 6 and Y.sub.1 and Y.sub.2 are amino acids with a sulfur, nitrogen or oxygen which is available for binding to metal ions, or can be made available for binding to metal ions; the biological-function domain is an amino acid sequence containing from 1 to about 20 amino acids located in any one or more of R.sub.1, R.sub.2 or R.sub.3 ; and those portions of R.sub.1, R.sub.2 and R.sub.